《贝伐珠单抗与化疗治疗晚期结肠癌的效果观察及对不良反应的影响》-理学论文，医学论文范文-论文范文参考-科学狗论文网

标题

贝伐珠单抗与化疗治疗晚期结肠癌的效果观察及对不良反应的影响

范文

应佳可杨翀孔颖苏燕燕

[摘要] 目的評价与分析贝伐珠单抗与化疗联合治疗晚期结肠癌的效果及对不良反应发生率的影响。方法以我院2017年1月～2019年12月期间接诊的结肠癌患者为研究对象，从中筛选60例结肠癌晚期患者，根据治疗方案的不同分为对照组（n=30）和观察组（n=30），对照组实施对症的化疗措施，观察组实施对症化疗+贝伐珠单抗联合治疗，比较两组患者的治疗效果、外周血循环肿瘤细胞（CTCs）阳性率和不良反应情况。结果两组患者的完全缓解例数和缓解率比较，差异均无统计学意义（P>0.05），观察组部分缓解、病情稳定和疾病控制率均高于对照组（P<0.05）;观察组治疗前后CTCs阳性率比较，差异无统计学意义（P>0.05），对照组治疗前后比较，差异有统计学意义（P<0.05），且观察组明显低于对照组（P<0.05）;两组患者的神经毒性、肝功能损伤和Ⅰ～Ⅱ度骨髓抑制比较，差异无统计学意义（P>0.05），而观察组的恶心、呕吐情况和Ⅲ～Ⅳ度骨髓抑制情况均低于对照组，差异有统计学意义（P<0.05）。结论贝伐珠单抗与化疗联合治疗晚期结肠癌，可以减缓疾病的进展，降低CTCs阳性率，并可减少恶心、呕吐的发生率，减弱骨髓抑制的程度，值得临床推广。

[关键词] 贝伐珠单抗;化疗;结肠癌;循环肿瘤细胞;不良反应

[中图分类号] R735.34? ? ? ? ? [文献标识码] B? ? ? ? ? [文章编号] 1673-9701（2020）28-0070-04

Observation of the efficacy of bevacizumab combined with chemotherapy in the treatment of advanced colon cancer and its impact on adverse reactions

YING Jiake? ?YANG Chong? ?KONG Ying? ?SU Yanyan

Department of General Surgery，Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine，Hangzhou 310003，China

[Abstract] Objective To evaluate and analyze the effect of bevacizumab combined with chemotherapy in the treatment of advanced colon cancer and its impact on the incidence of adverse reactions. Methods A total of 60 patients with advanced colon cancer were screened from colon cancer patients in our hospital from January 2017 to December 2019 and were divided into a control group（n=30） and an observation group（n=30） according to different treatment schemes. The former group implemented symptomatic chemotherapy， and the latter group implemented symptomatic chemotherapy+bevacizumab combination therapy. The treatment effect， the positive rate of CTCs and adverse reactions between the two groups were compared. Results There were no significant differences in the number of complete remission cases and remission rate between the two groups（P>0.05）. The partial remission， stable condition and disease control rate of the observation group were higher than those of the control group（P<0.05）. After treatment， the positive rate of CTCs of the observation group was not significantly different from that before treatment（P>0.05）. There was significant difference in the positive rate of CTCs in the control group before and after treatment（P<0.05）. The positive rate of CTCs in the observation group was significantly lower than that in the control group（P<0.05）. There were no significant differences in neurotoxicity，liver function damage and Ⅰ-Ⅱdegree bone marrow suppression between two groups（P>0.05）， while the nausea， vomiting and Ⅲ-Ⅳ degree bone marrow suppression in the observation group were lower than those in the control group（P<0.05）. Conclusion The combination of bevacizumab and chemotherapy in the treatment of advanced colon cancer can slow the disease progression，reduce the positive rate of CTCs， and can reduce the incidence of nausea and vomiting， and reduce the degree of bone marrow suppression. It is worthy of clinical promotion.

随便看

科学优质学术资源、百科知识分享平台，免费提供知识科普、生活经验分享、中外学术论文、各类范文、学术文献、教学资料、学术期刊、会议、报纸、杂志、工具书等各类资源检索、在线阅读和软件app下载服务。